Eng WK - Search Results

1

The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding.

Koser PL, Eng WK, Bossard MJ, McLaughlin MM, Cafferkey R, Sathe GM, Faucette L, Levy MA, Johnson RK, Bergsma DJ, Livi GP. Koser PL, et al. Among authors: eng wk. Gene. 1993 Jul 30;129(2):159-65. doi: 10.1016/0378-1119(93)90264-4. Gene. 1993. PMID: 8325502

2

The CYP2 gene of Saccharomyces cerevisiae encodes a cyclosporin A-sensitive peptidyl-prolyl cis-trans isomerase with an N-terminal signal sequence.

Koser PL, Bergsma DJ, Cafferkey R, Eng WK, McLaughlin MM, Ferrara A, Silverman C, Kasyan K, Bossard MJ, Johnson RK, Porterd TG, Levy MA, Livi GP. Koser PL, et al. Among authors: eng wk. Gene. 1991 Dec 1;108(1):73-80. doi: 10.1016/0378-1119(91)90489-x. Gene. 1991. PMID: 1761234

3

Catalytic and ligand binding properties of the FK506 binding protein FKBP12: effects of the single amino acid substitution of Tyr82 to Leu.

Bossard MJ, Bergsma DJ, Brandt M, Livi GP, Eng WK, Johnson RK, Levy MA. Bossard MJ, et al. Among authors: eng wk. Biochem J. 1994 Jan 15;297 ( Pt 2)(Pt 2):365-72. doi: 10.1042/bj2970365. Biochem J. 1994. PMID: 7507662 Free PMC article.

4

The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth.

Eng WK, Faucette L, McLaughlin MM, Cafferkey R, Koltin Y, Morris RA, Young PR, Johnson RK, Livi GP. Eng WK, et al. Gene. 1994 Dec 30;151(1-2):61-71. doi: 10.1016/0378-1119(94)90633-5. Gene. 1994. PMID: 7530227

5

Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.

Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, Faucette L, Eng WK, Johnson RK, Livi GP. Cafferkey R, et al. Among authors: eng wk. Mol Cell Biol. 1993 Oct;13(10):6012-23. doi: 10.1128/mcb.13.10.6012-6023.1993. Mol Cell Biol. 1993. PMID: 8413204 Free PMC article.

6

Expression of human recombinant cAMP phosphodiesterase isozyme IV reverses growth arrest phenotypes in phosphodiesterase-deficient yeast.

McHale MM, Cieslinski LB, Eng WK, Johnson RK, Torphy TJ, Livi GP. McHale MM, et al. Among authors: eng wk. Mol Pharmacol. 1991 Feb;39(2):109-13. Mol Pharmacol. 1991. PMID: 1847489

7

Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.

Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB. Chaturvedi P, et al. Among authors: eng wk. Oncogene. 1999 Jul 15;18(28):4047-54. doi: 10.1038/sj.onc.1202925. Oncogene. 1999. PMID: 10435585

8

Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.

Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK. Woessner RD, et al. Among authors: eng wk. Oncol Res. 1992;4(11-12):481-8. Oncol Res. 1992. PMID: 1338578

9

Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.

Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Tan KB, et al. Among authors: eng wk. J Natl Cancer Inst. 1989 Nov 15;81(22):1732-5. doi: 10.1093/jnci/81.22.1732. J Natl Cancer Inst. 1989. PMID: 2553992

10

Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin.

Eng WK, Faucette L, Johnson RK, Sternglanz R. Eng WK, et al. Mol Pharmacol. 1988 Dec;34(6):755-60. Mol Pharmacol. 1988. PMID: 2849043

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters